Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

GPR6 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Immunohistochemical identification of GPR6 Receptor in small intestine
GPR6 (IHC-grade), G Protein-Coupled Receptor 6...
The GPR6 antibody is directed against the distal end of the carboxyl-terminal tail of mouse, rat and human GRP6. It can be used to detect total GPR6receptors in Western blots independent of phosphorylation. The GPR6 antibody can also be...
$ 400.00 *
NEW
Validation of the GPR6 Receptor in transfected HEK293 cells.
GPR6 (non-phospho), G protein-coupled Receptor...
The non-phospho-GPR6 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human GPR6. It can be used to detect total GPR6 receptors in Western blots independent of phosphorylation. The GPR6 antibody can...
$ 400.00 *

GPR6 (G Protein-Coupled Receptor 6) is an orphan GPCR that exhibits constitutive activity, primarily coupling to the Gs protein to increase intracellular cAMP levels. It shares structural similarity with cannabinoid receptors and is part of the MECA (melanocortin, endothelial differentiation gene, cannabinoid, adenosine) receptor cluster. GPR6 is predominantly expressed in the central nervous system, with particularly high levels in the striatum and other brain regions involved in motor control and cognitive function. It is also found at lower levels in peripheral tissues, though its functional roles outside the brain are less well understood. GPR6 is considered a potential pharmacological target, especially in the context of neurodegenerative and neuropsychiatric disorders. It has been implicated in Parkinson’s disease and Huntington’s disease due to its role in modulating dopaminergic signaling and neuronal activity. Several synthetic inverse agonists of GPR6 have shown promise in preclinical models, making it a subject of growing interest in drug discovery, particularly for movement disorders. For more information on GPR6 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

GPR6 (G Protein-Coupled Receptor 6) is an orphan GPCR that exhibits constitutive activity, primarily coupling to the Gs protein to increase intracellular cAMP levels. It shares structural... read more »
Close window
GPR6 Receptor Antibodies

GPR6 (G Protein-Coupled Receptor 6) is an orphan GPCR that exhibits constitutive activity, primarily coupling to the Gs protein to increase intracellular cAMP levels. It shares structural similarity with cannabinoid receptors and is part of the MECA (melanocortin, endothelial differentiation gene, cannabinoid, adenosine) receptor cluster. GPR6 is predominantly expressed in the central nervous system, with particularly high levels in the striatum and other brain regions involved in motor control and cognitive function. It is also found at lower levels in peripheral tissues, though its functional roles outside the brain are less well understood. GPR6 is considered a potential pharmacological target, especially in the context of neurodegenerative and neuropsychiatric disorders. It has been implicated in Parkinson’s disease and Huntington’s disease due to its role in modulating dopaminergic signaling and neuronal activity. Several synthetic inverse agonists of GPR6 have shown promise in preclinical models, making it a subject of growing interest in drug discovery, particularly for movement disorders. For more information on GPR6 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

Recently viewed